Aristotle University Of Thessaloniki (AUTH)
Investigation of the aggregation mechanism of the pathological ataxin-1 protein and potential pharmacological inhibitory approaches
Abstract
dc:descriptionPolyglutamine diseases (polyQ) comprise a group of neurodegenerative disorders associated with a trinucleotide (CAG) repeat expansion within the coding region of diverse genes. In the case of spinocerebellar ataxia type 1 (SCA1), CAG expansions in ATXN1 gene results in longer polyglutamine chains in the produced protein. A striking feature of the polyQ ataxin-1 protein is its ability to form toxic species and misfold into oligomers that slowly aggregate into larger insoluble inclusions in the nucleus. To investigate the role of polyQ IIBs in SCA1 pathogenesis, we generated a novel protein aggregation model by inducible overexpression of the mutant ATXN1(Q82) isoform in human neuroblastoma SH-SY5Y cells and developed a reproducible protocol for isolating ATXN1 insoluble inclusions. Biophysical studies showed that polyQ IIBs are enriched in RNA molecules, which were further analyzed by next generation sequencing. Protein interaction networks analysis suggested that sequestration of essential RNA transcripts within ATXN1(Q82) inclusions disrupts ribosomal function, leading to errors in protein synthesis and overall proteome instability. These findings shed new light on the molecular pathogenesis of SCA1, highlighting the critical impact of polyQ IIBs on critical cellular processes. Additionally, we explored the interaction between ATXN1 and MED15, a protein that significantly enhances ATXN1 aggregation and toxicity. To explore the effect of MED15 on polyQ-expanded ATXN1 aggregation, we generated an overexpression cell model in MSCs, characterized by stable expression of mCherry-MED15 and inducible expression of YFP-ATXN1(Q82) transgenes. Next, we predicted ATXN1 and MED15 protein structures and simulated their interaction. Predicted interaction sites between ATXN1 and MED15 were validated using LuTHy, a mammalian cell-based assay which enables the detection and quantification of PPIs. The validated interaction site encompasses amino acids 99-163 of ATXN1 and 548-665 of MED15. A targeted in-silico screen for inhibitors of this PPI within the ATXN1 region 99-163 identified 24 compounds with their effects further tested in high-throughput LuTHy assays. Further analysis also revealed that the ATXN1 interaction site modulates its dimerization, emphasizing its significance in polyQ aggregation. Moreover, focusing on the AXH domain of ataxin-1, which is critical for the dimerization of the mutant polyQ protein, we performed an in silico screening and identified 42 compounds that bind to the AXH domain of ATXN1. In parallel, we set up a LuTHy assay for the quantification of its dimerization. Selected compounds were tested to determine if they could inhibit the dimerization of the AXH domain in high-throughput LuTHy assays. Hit compounds for ATXN1-MED15 interaction and AXH dimerization were further evaluated for their ability to inhibit the dimerization of full-length ATXN1 protein in LuTHy assays. Finally, compounds with known neuroprotective and anti-aggregation properties were tested for their ability to inhibit ATXN1(Q82) aggregation in primary human cells, using a filter retardation assay and and G4-Mal was found to reduce the quantity of insoluble polyQ IIBs. However, Caffeic acid, Gallic acid, and their derivatives did not show such effects.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gkekas, Ioannis
- Γκέκας, Ιωάννης
Subjects
dc:subject × 12Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56990